<ul class="ProvisionList"><li><p class="Subsection amending&#xA;        "><strong><a id="s-6."><span class="sectionLabel">6.</span></a></strong> (1) Section 30 of the Act is amended by adding the following after subsection (1.1):</p><section><div class="AmendedText"><ul class="ProvisionList"><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Regulations — therapeutic products</h6><p class="Subsection">(1.2) Without limiting the power conferred by any other subsection of this section, the Governor in Council may make regulations</p><ul class="ProvisionList"><li><p class="Paragraph">(<em>a</em>) respecting the issuance of authorizations — including licences — that authorize, as the case may be, the import, sale, advertisement, manufacture, preparation, preservation, packaging, labelling, storage or testing of a therapeutic product, and the amendment, suspension and revocation of such authorizations;</p></li><li><p class="Paragraph">(<em>b</em>) authorizing the Minister to impose terms and conditions on authorizations referred to in paragraph (<em>a</em>), including existing authorizations, and to amend those terms and conditions;</p></li><li><p class="Paragraph">(<em>b.1</em>) requiring the Minister to ensure that decisions with regard to the issuance, amendment, suspension and revocation of authorizations referred to in paragraph (<em>a</em>), and to the imposition and amendment of terms and conditions referred to in paragraph (<em>b</em>), along with the reasons for those decisions, are publicly available;</p></li><li><p class="Paragraph">(<em>c</em>) requiring holders of a therapeutic product authorization that authorizes the import or sale of a therapeutic product for a clinical trial or investigational test involving human subjects, or former holders of such an authorization, to provide the Minister, after the trial or test is completed or discontinued, or, if the authorization is suspended or revoked, after the suspension or revocation, with safety information that the holders or former holders receive or become aware of about the therapeutic product;</p></li><li><p class="Paragraph">(<em>c.1</em>) defining <span class="DefinedTerm"><dfn>“clinical trial”</dfn></span> and <span class="DefinedTerm"><dfn>“investigational test”</dfn></span> for the purposes of this Act;</p></li><li><p class="Paragraph">(<em>d</em>) requiring holders of a therapeutic product authorization to provide the Minister with information, in respect of any serious risk of injury to human health, that the holders receive or become aware of and that is relevant to the safety of the therapeutic product to which the authorization relates, regarding</p><ul class="ProvisionList"><li><p class="Subparagraph">(i) risks that have been communicated outside Canada, and the manner of the communication,</p></li><li><p class="Subparagraph">(ii) changes that have taken place to labelling outside Canada, and</p></li><li><p class="Subparagraph">(iii) recalls, reassessments and suspensions or revocations of authorizations, including licences, in respect of a therapeutic product, that have taken place outside Canada;</p></li></ul></li><li><p class="Paragraph">(<em>d.1</em>) specifying the business information obtained under this Act in relation to an authorization under paragraph (<em>a</em>) that is not confidential business information, or the circumstances in which business information obtained under this Act in relation to such an authorization ceases to be confidential business information;</p></li><li><p class="Paragraph">(<em>d.2</em>) authorizing the Minister to disclose, without notifying the person to whose business or affairs the information relates or obtaining their consent, business information that, under regulations made under paragraph (<em>d.1</em>),</p><ul class="ProvisionList"><li><p class="Subparagraph">(i) is not confidential business information, or</p></li><li><p class="Subparagraph">(ii) has ceased to be confidential business information;</p></li></ul></li><li><p class="Paragraph">(<em>e</em>) respecting modifications of labels and modifications and replacements of packages referred to in section 21.2;</p></li><li><p class="Paragraph">(<em>f</em>) respecting the recall of a therapeutic product or the sale of a therapeutic product that is the subject of a recall; and</p></li><li><p class="Paragraph">(<em>g</em>) prescribing anything that is to be prescribed under section 21.71.</p></li></ul></li></ul></div></section></li><li><p class="Subsection amending&#xA;        ">(2) Subsection 30(1.2) of the Act is amended by striking out “and” at the end of paragraph (<em>f</em>) and by adding the following after paragraph (<em>f</em>):</p><section><div class="AmendedText"><ul class="ProvisionList"><li><p class="Paragraph">(<em>f.1</em>) respecting assessments referred to in section 21.31, and the provision of the results of the assessments to the Minister;</p></li><li><p class="Paragraph">(<em>f.2</em>) requiring the Minister to ensure that decisions with regard to the making of orders under section 21.31, along with the reasons for those decisions, are publicly available;</p></li><li><p class="Paragraph">(<em>f.3</em>) respecting the compilation of information, the conducting of tests and studies and the monitoring of experience that are referred to in paragraph 21.32(<em>a</em>), and the provision to the Minister of the information or results referred to in paragraph 21.32(<em>b</em>); and</p></li></ul></div></section></li><li><p class="Subsection amending&#xA;        ">(3) Subsection 30(1.2) of the Act is amended by striking out “and” at the end of paragraph (<em>f</em>) and by adding the following after paragraph (<em>g</em>):</p><section><div class="AmendedText"><ul class="ProvisionList"><li><p class="Paragraph">(<em>h</em>) defining <span class="DefinedTerm"><dfn>“serious adverse drug reaction”</dfn></span> and <span class="DefinedTerm"><dfn>“medical device incident”</dfn></span> for the purposes of this Act;</p></li><li><p class="Paragraph">(<em>i</em>) respecting the provision by health care institutions referred to in section 21.8 to the Minister of information referred to in that section; and</p></li><li><p class="Paragraph">(<em>j</em>) prescribing anything that is to be prescribed under section 21.8.</p></li></ul></div></section></li><li><p class="Subsection amending&#xA;        ">(4) Section 30 of the Act is amended by adding the following after subsection (1.2):</p><section><div class="AmendedText"><ul class="ProvisionList"><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Consideration of existing information management systems</h6><p class="Subsection">(1.3) Before recommending to the Governor in Council that a regulation be made under paragraph (1.2)(<em>i</em>) or (<em>j</em>), the Minister shall take into account existing information management systems, with a view to not recommending the making of regulations that would impose unnecessary administrative burdens.</p></li></ul></div></section></li><li><p class="Subsection amending&#xA;        ">(5) The portion of subsection 30(2) of the Act before paragraph (<em>a</em>) is replaced by the following:</p><section><div class="AmendedText"><ul class="ProvisionList"><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Regulations respecting drugs manufactured outside Canada</h6><p class="Subsection">(2) Without limiting the power conferred by any other subsection of this section, the Governor in Council may make such regulations governing, regulating or prohibiting</p></li></ul></div></section></li><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>1994, c. 47, s. 117</h6><p class="Subsection amending&#xA;        ">(6) Subsection 30(3) of the Act is replaced by the following:</p><section><div class="AmendedText"><ul class="ProvisionList"><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Regulations — North American Free Trade Agreement and WTO Agreement</h6><p class="Subsection">(3) Without limiting the power conferred by any other subsection of this section, the Governor in Council may make any regulations that the Governor in Council considers necessary for the purpose of implementing, in relation to drugs, Article 1711 of the North American Free Trade Agreement or paragraph 3 of Article 39 of the Agreement on Trade-related Aspects of Intellectual Property Rights set out in Annex 1C to the WTO Agreement.</p></li></ul></div></section></li><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>2004, c. 23, s. 2</h6><p class="Subsection amending&#xA;        ">(7) Subsection 30(5) of the Act is replaced by the following:</p><section><div class="AmendedText"><ul class="ProvisionList"><li><h6 class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Regulations to implement General Council Decision</h6><p class="Subsection">(5) Without limiting the power conferred by any other subsection of this section, the Governor in Council may make any regulations that the Governor in Council considers necessary for the purpose of implementing the General Council Decision.</p></li></ul></div></section></li></ul>
